Evidence map›Paper›PMID 34203149›Full record

ArticleViruses2021

Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform.

Stephen R Welch, Jessica R Spengler, Sarah C Genzer, Payel Chatterjee, Mike Flint, Éric Bergeron, Joel M Montgomery, Stuart T Nichol, César G Albariño, Christina F Spiropoulou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Stephen R WelchViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.ORCID 0000-0002-6905-8521
Jessica R SpenglerViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.ORCID 0000-0002-5383-0513
Sarah C GenzerViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.
Payel ChatterjeeViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.
Mike FlintViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.ORCID 0000-0002-5373-787X
Éric BergeronViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.ORCID 0000-0003-3398-8628
Joel M MontgomeryViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.
Stuart T NicholViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.
César G AlbariñoViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.
Christina F SpiropoulouViral Special Pathogens Branch, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30329, USA.
Centers for Disease Control and Prevention · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lujo virus (LUJV), a highly pathogenic arenavirus, was first identified in 2008 in Zambia. To aid the identification of effective therapeutics for LUJV, we developed a recombinant reporter virus system, confirming reporter LUJV comparability with wild-type virus and its utility in high-throughput antiviral screening assays. Using this system, we evaluated compounds with known and unknown efficacy against related arenaviruses, with the aim of identifying LUJV-specific and potential new pan-arenavirus antivirals. We identified six compounds demonstrating robust anti-LUJV activity, including several compounds with previously reported activity against other arenaviruses. These data provide critical evidence for developing broad-spectrum antivirals against high-consequence arenaviruses.

Indexed as

AnimalsAntiviral AgentsArenaviridae InfectionsArenavirusCell Line, TumorChlorocebus aethiopsGenome, ViralGreen Fluorescent ProteinsHumansLujo virusMicrobial Sensitivity TestsRecombinant ProteinsVero CellsVirus InternalizationAntiviral AgentsGreen Fluorescent ProteinsRecombinant Proteinsantiviral screenarenavirusemerging virusesLujo virusreporter virusreverse geneticstherapeuticviral hemorrhagic fever

Identifiers

PMID34203149
PMCPMC8310135
OpenAlexW3175113283

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.